ArticleOncology and therapy2026
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04500535 (A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNivolumab is approved for the treatment of advanced non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study evaluated long-term outcomes, safety and feasibility of immunotherapy rechallenge in French patients with previously treated aNSCLC in routine practice. We report the results of the final 24-month analysis.
methodsLIST was a longitudinal, prospective, observational study enrolling patients with aNSCLC who had received ≥ 1 prior line of therapy and were initiating treatment with nivolumab. Patients were classified into three cohorts according to prior immunotherapy exposure: immunotherapy-naïve (cohort 1); immunotherapy-experienced and discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort 2); and discontinued because of immunotherapy-related toxicity (cohort 3). The primary endpoint was time to treatment discontinuation (TTD). Secondary endpoints included overall survival (OS), progression-free survival (PFS), response at 24 months, safety and quality of life (QoL).
resultsA total of 522 patients were included (cohort 1, n = 280; cohort 2, n = 197; cohort 3, n = 45). Median TTD was 3.8, 3.2 and 3.4 months in cohorts 1, 2 and 3, respectively, with 24-month discontinuation-free rates of 7.9%, 6.0% and 7.1%. Median OS was 12.3, 9.5 and 9.8 months, and median PFS was 3.2, 2.6 and 3.9 months across cohorts 1, 2 and 3, respectively. Disease progression was the most common reason for nivolumab discontinuation. Numerically higher discontinuation-free rates were observed in patients who were younger (< 75 years), had better performance status, had non-squamous histology, were current smokers or had demonstrated prolonged benefit with prior immunotherapy. Safety outcomes were consistent with the established nivolumab profile, with no new safety signals. Among patients with available data, QoL changes were generally small.
conclusionsConsistent with results from previous analyses, this final 24-month analysis of LIST demonstrated real-world effectiveness and safety of nivolumab in patients with aNSCLC. Nivolumab rechallenge appears to be an option in selected patients, based on patient and disease characteristics and prior immunotherapy history.
trial registrationClinicalTrials.gov identifier NCT04500535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.